Transition Metal-Catalyzed Alkene Functionalization

NIH RePORTER · NIH · R35 · $305,031 · view on reporter.nih.gov ↗

Abstract

Project Summary After carbon and hydrogen; oxygen, nitrogen, and fluorine are the three most common elements found in pharmaceuticals and drug candidates. Lead identification and optimization is typically the longest part of the drug discovery process, taking about five out of the average fifteen years, to bring a drug to market. This is partially due to the requirement to synthesize and test of a large number of potential drug candidates through structure activity relationship (SAR) studies. As such, the development of new organic methodologies for the rapid synthesis of organic molecules is of utmost importance to synthetic chemists. The research described herein focuses on the development of novel approaches for the synthesis of C–N, C–O, C–S, C–P, C–F, C–Cl, C–Br, and C–B bonds, in a selective and expedient manner. Moreover, it seeks to allow for divergent synthesis; where from a single common intermediate libraries of potential pharmaceuticals could be synthesized in a single synthetic transformation simply by varying the reagents. More specifically, the proposal focuses on the development of an array of carbon-carbon double bond difunctionalization of using a copper or palladium catalyst.

Key facts

NIH application ID
10842932
Project number
2R35GM125029-06
Recipient
UNIVERSITY OF TEXAS AT AUSTIN
Principal Investigator
Kami Lee Hull
Activity code
R35
Funding institute
NIH
Fiscal year
2024
Award amount
$305,031
Award type
2
Project period
2017-08-01 → 2029-08-31